Johnson & Johnson (JNJ) Stock Price & Analysis
Johnson & Johnson (JNJ) rose 2.08% to USD 237 as of June 9, 2026 at 22:42 UTC, according to Nexqual real-time market data.
JNJ last closed at USD 232.16; the session ranged USD 230.41–237.71 on volume of 8,191,819 shares. Market capitalization is $570.51B, with a 52-week range of USD 149.04–251.71 (NYQ). Source: Nexqual, June 9, 2026 at 22:42 UTC.
Key Statistics (as of June 9, 2026 at 22:42 UTC)
| Price | USD 237 |
|---|---|
| Change | ▲ 2.08% (up) |
| Previous Close | USD 232.16 |
| Open | USD 232.38 |
| Day Range | USD 230.41 – 237.71 |
| 52-Week Range | USD 149.04 – 251.71 |
| Volume | 8,191,819 shares |
| Market Cap | $570.51B |
| Exchange | NYQ |
Technical Analysis (JNJ)
Nexqual's technical model rates JNJ "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 22:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.79 (neutral) |
| vs SMA50 | Above (USD 231.24) |
| MACD | 0.41 (positive) |
Analyst Ratings (JNJ)
Wall Street analysts rate JNJ "Buy" based on 23 analysts, with a mean price target of USD 252.87 (range USD 155–285), per Nexqual as of June 9, 2026 at 22:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 252.87 |
| High Target | USD 285 |
| Low Target | USD 155 |
| Buy / Hold / Sell | 15 / 8 / 1 |
Earnings (JNJ)
| Next Earnings Date | 2026-07-15 |
|---|---|
| EPS Estimate | USD 2.85 |
| Revenue Estimate | $25.01B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.7 vs est 2.68 ▲ beat |
| 2025-12-31 | USD 2.46 vs est 2.46 ▼ miss |
| 2025-09-30 | USD 2.8 vs est 2.76 ▲ beat |
| 2025-06-30 | USD 2.77 vs est 2.68 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Financials & Fundamentals (JNJ)
| Total Revenue | $96.36B |
|---|---|
| Revenue Growth (YoY) | +9.90% |
| Gross Margin | +68.04% |
| Operating Margin | +27.41% |
| Profit Margin | +21.83% |
| ROE | +26.42% |
| Debt / Equity | 67.73 |
| Current Ratio | 1.03 |
| Total Cash | $22.05B |
| Total Debt | $54.99B |
| Free Cash Flow | $12.51B |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Financial Health Score (JNJ)
Nexqual rates Johnson & Johnson's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:42 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 27% |
| Balance Sheet | Solid — $22.1B cash vs $55.0B debt |
| Cash Flow | Solid — FCF $12.5B, 13% margin |
| Efficiency | Strong — ROE 26%, ROA 8.4% |
Ownership (JNJ)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +76.85% |
| Shares Outstanding | 2.41B |
| Float | 2.40B |
| Short % of Float | +1.07% |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
Leadership (JNJ)
Johnson & Johnson is led by Joaquin Duato (age 62), CEO & Chairman, per Nexqual as of June 9, 2026 at 22:42 UTC.
| CEO & Chairman | Joaquin Duato (age 62) |
|---|---|
| Executive VP & CFO | Joseph James Wolk (age 58) |
| Executive VP & Worldwide Chairman of Innovative Medicine | Jennifer L. Taubert (age 61) |
| Executive Vice President of Innovative Medicine and R & D | John C. Reed (age 67) |
| Executive VP & Worldwide Chairman of MedTech | Timothy Schmid (age 55) |
Major Backers & Investors (JNJ)
Notable institutional backers of Johnson & Johnson include JPMorgan, Morgan Stanley, State Farm Mutual Automobile Insurance Co, according to Nexqual as of June 9, 2026 at 22:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 2.62% |
| Morgan Stanley | 1.86% |
| State Farm Mutual Automobile Insurance Co | 1.31% |
| Fidelity | 1.28% |
| Bank of America Corporation | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.31% |
| BlackRock | 10.15% |
| State Street | 6.74% |
| Geode Capital | 2.46% |
| Northern Trust | 1.22% |
Source: Nexqual, June 9, 2026 at 22:42 UTC.
From Johnson & Johnson's Latest SEC 10-K Filing (filed 2026-02-11)
Partnerships
- In January 2026, the Company reached an agreement with the U.S.
- Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PG | Procter & Gamble Company (The) | USD 148.67 | ▲ 1.45% |
| PFE | Pfizer, Inc. | USD 25.7 | ▼ 1.31% |
| MRK | Merck & Company, Inc. | USD 119.6 | ▼ 0.99% |
| KO | Coca-Cola Company (The) | USD 81.34 | ▲ 2.34% |
| XOM | Exxon Mobil Corporation | USD 148.91 | ▼ 0.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:42 UTC. This page is informational and not investment advice.